Avanos Medical, Inc.

Avanos Medical, Inc.

24.99
USD
+0.01
(+0.04%)
-1.59EPS
653.89MMarket Cap

Total Valuation

USD

As of March 31, 2026, Avanos Medical, Inc. carries a market capitalization of 653.89M, placing it among publicly traded companies globally. Its enterprise value stands at 726.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap653.89M
Enterprise Value726.69M

Important Dates

Avanos Medical, Inc.'s next confirmed earnings release is scheduled for August 11, 2026.

Earnings Date8/11/2026

Share Statistics

As of March 31, 2026, Avanos Medical, Inc. has 46.67M shares outstanding.

Shares Outstanding46.67M

Valuation Ratios

These figures are as of March 31, 2026. The price-to-sales ratio is 0.91, and the price-to-book ratio stands at 0.84.

PS Ratio0.91
PB Ratio0.84
P/TBV Ratio2.39
P/FCF Ratio17.81
P/OCF Ratio17.71

Enterprise Valuation

These figures are as of March 31, 2026. The EV/Sales ratio of 1.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 726.69M versus a market cap of 653.89M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.02

Financial Position

As of March 31, 2026, Avanos Medical, Inc. maintains a current ratio of 2.48, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.70, indicating elevated leverage, while an interest coverage ratio of -3.26 demonstrates limited ability to service its debt obligations.

Current Ratio2.48
Quick Ratio1.29
Debt / Equity17.70
Debt / EBITDA-5.89
Interest Coverage-3.26

Financial Efficiency

USD

Over the twelve months ended March 31, 2026, Avanos Medical, Inc. posted a negative return on equity (ROE) of -9.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.90, reflecting losses generated across the asset base. The company generates approximately 317,190.96 in revenue per employee across its workforce of 2,257.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.56 indicates how many times Avanos Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-9.18
Return on Assets (ROA)-6.90
Revenue Per Employee317,190.96
Employee Count2,257.00
Inventory Turnover2.56

Taxes

USD

Over the twelve months ended March 31, 2026, Avanos Medical, Inc. recorded 6.10M in income tax expense. The company reported a pretax loss of -68.30M and -74.40M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax6.10M

Stock Price Statistics

USD

As of the close on July 24, 2026, Avanos Medical, Inc.'s stock has gained approximately 110.35% over the past 52 weeks. The 50-day moving average sits at 24.90, while the 200-day moving average is 16.92.

52-Week Price Change110.35%
50-Day Moving Average24.90
200-Day Moving Average16.92

Income Statement

USD

Over the twelve months ended March 31, 2026, Avanos Medical, Inc. generated 715.90M in revenue and converted that into -74.40M in net income, yielding earnings per share of -1.59. EBITDA reached -23.50M, while operating income came in at 14.00M.

Revenue715.90M
Gross Profit358.30M
Operating Income14.00M
Pretax Income-68.30M
Net Income-74.40M
EBITDA-23.50M
EBIT-63.00M
Earnings Per Share (EPS)-1.59

Balance Sheet

USD

As of March 31, 2026, Avanos Medical, Inc. holds 65.60M in cash and equivalents against 138.40M in total debt, resulting in a net debt position of 32.60M. Total book value stands at 782.10M, with working capital of 193.80M providing operational flexibility.

Cash & Cash Equivalents65.60M
Total Debt138.40M
Net Debt32.60M
Equity (Book Value)782.10M
Book Value Per Share16.76
Working Capital193.80M

Cash Flow

USD

Avanos Medical, Inc. produced 36.70M in operating cash flow over the twelve months ended March 31, 2026.

Operating Cash Flow36.70M
Free Cash Flow36.70M
FCF Per Share0.79

Margins

Over the twelve months ended March 31, 2026, Avanos Medical, Inc. posted a gross margin of 50.05, reflecting its pricing power and cost economics. The operating margin of 1.96 and net profit margin of -10.39 provide insight into operational efficiency.

Gross Margin50.05
Operating Margin1.96
Pretax Margin-9.54
Profit Margin-10.39
EBITDA Margin-3.28

Dividends & Yields

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 5.62, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.70, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Avanos Medical, Inc. shareholders.

Shareholder Yield1.70
FCF Yield5.62

Scores

As of March 31, 2026, Avanos Medical, Inc. has an Altman Z-Score of 1.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.30